Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 18;13(3):470-474.
doi: 10.1021/acsmedchemlett.1c00640. eCollection 2022 Mar 10.

QuatCy-I2 and MHI-I2 in Photodynamic Therapy

Affiliations

QuatCy-I2 and MHI-I2 in Photodynamic Therapy

Sopida Thavornpradit et al. ACS Med Chem Lett. .

Abstract

MHI-I2 (1) and QuatCy-I2 (2) were compared in terms of properties important for early-stage photodynamic therapy preclinical candidates. Thus, experiments were performed to monitor dark cytotoxicities, light/dark cytotoxicity ratios, selectivity of localization in tumors over other organs, and clearance from the plasma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
Dark cytotoxicities of compounds A (IC50-dark = 19.2 ± 0.97 μM), B (>100 μM), 1 (11.4 ± 0.47 μM), and 2 (62.4 ± 9.1 μM) after they were incubated for 48 h with U-87 MG. Data points show mean ± SD (n = 8).
Figure 2
Figure 2
Light and dark cytotoxicities of (a) 1 and (b) 2 on U87-MG cells after incubation for 6 and 24 h in DMEM containing 10% FBS. Cells were washed twice with pH 7.4 PBS, and the medium was changed to pH 7.4 ACAS, followed by irradiation (3.8 mW/cm2) for 20 min and dark incubation for 24 h. Viabilities were determined using AlamarBlue. Data points show mean ± SD (n = 8).
Figure 3
Figure 3
Biodistribution and clearance of compounds 1 and 2 in CD-1 mice (25 nmol of each compound injected iv 4 h prior to imaging). (a) Shown are representative (left) color and (right) NIR fluorescence images of the thoracic cavity, abdominal cavity, and post mortem in resected organs. (b) Signal-to-background ratio (SBR) for resected organs (Or) against muscle (Mu). (c) Percent injected dose (%ID) of compounds in plasma at each time point calculated from fluorescence signal intensities 4 h postadministration (n = 3 or 5, mean ± SD). Abbreviations: Bl, bladder; Du, duodenum; Ga, gall bladder; He, heart; In, intestine; Ki, kidney; Mu, muscle; Li, liver; Lu, lung; Pa, pancreas; Sp, spleen. Excitation was at 760 nm (4 mW/cm2), and emission was at 790–850 nm. All NIR fluorescence images for each fluorophore were normalized identically for all conditions during an experiment.
Figure 4
Figure 4
Tumor targeting and biodistribution of compounds 1 and 2 in NIT-1 tumor-bearing mice. Each compound (35 nmol) was injected iv 4 h prior to imaging. Shown are representative (left) color and (right) NIR fluorescence images of (a) the thoracic cavity, (b) the abdominal cavity, (c) resected organs, (d) neck/axillary, (e) tumor, and (f) resected tumor (Tu) and muscle (Mu). Arrows indicate lymph nodes. The tumor-to-background ratios (TBRs) of 1 and 2 were 6.5 ± 2.55 and 8.98 ± 2.17, respectively. Data points are displayed as mean ± SD, and the p values were evaluated using Student’s t test. Abbreviations: Bl, bladder; BM, bone marrow; Du, duodenum; Ga, gall bladder; He, heart; In, intestine; Ki, kidney; Mu, muscle; Li, liver; Lu, lung; Pa, pancreas; Sp, spleen; Ur, ureter. Excitation was at 760 nm (4 mW/cm2), and emission was at 790–850 nm. All NIR fluorescence images for each fluorophore were normalized identically for all conditions during an experiment.

Similar articles

Cited by

References

    1. Foote C. S. Definition of Type I and Type II Photosensitized Oxidation. Photochem. Photobiol. 1991, 54, 659.10.1111/j.1751-1097.1991.tb02071.x. - DOI - PubMed
    1. Plaetzer K.; Krammer B.; Berlanda J.; Berr F.; Kiesslich T. Photophysics and Photochemistry of photodynamic Therapy: Fundamental Aspects. Lasers Med. Sci. 2009, 24, 259–268. 10.1007/s10103-008-0539-1. - DOI - PubMed
    1. Mehraban N.; Freeman H. S. Developments in PDT Sensitizers for Increased Selectivity and Singlet Oxygen Production. Materials 2015, 8, 4421–4456. 10.3390/ma8074421. - DOI - PMC - PubMed
    1. Cheng P. H.; Pu K. Y. Molecular imaging and disease theranostics with renal-clearable optical agents. Nat. Rev. Mater. 2021, 6, 1095–1113. 10.1038/s41578-021-00328-6. - DOI
    1. Wu L. L.; Huang J. G.; Pu K. Y.; James T. D. Dual-locked spectroscopic probes for sensing and therapy. Nat. Rev. Chem. 2021, 5, 406–421. 10.1038/s41570-021-00277-2. - DOI - PubMed